Belarus Media Internet Information about media, internet, technology and services Related Articles
ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX ), a clinical-stage company with multiple therapies designed to treat cancer and other diseases affected in the complaint area, today announced that it plans to hold a conference call on Monday, November 13, 2023 at 8:30 a.m. ET to discuss its Financial results for the quarter ending September 30, 2023 and provide the company with updates.
Individuals may join the conference call by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (national) and using the conference call Number ID: 13741546. Participants are requested to call within 15 minutes before the start of the meeting to register. Investors and the public can access the telecast of this meeting and its documents through the “News & Media” section of the company’s website, https://www.therivabio.comin the section “Events” or click hereup to 90 days after the telephone meeting.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified medical-stage company developing therapies designed to treat cancer and other diseases in areas of high need. The Company has developed a new oncolytic adenovirus platform designed for intravenous, intravitreal, and antibiotic therapy to induce tumor cell death, improving access to integrated oncology treatments. to the tumor, and to strengthen and stimulate the response from the patient’s body. the system. The Company’s main competitors are: (1) VCN-01, an oncolytic adenovirus designed to replicate and infect cancer cells, and induce tumor stromal disruption that is functional important in the body and the immune system for the treatment of cancer; (2) SYN-004 (ribaxamasse), designed to degrade intravenous beta-lactam antibiotics in the gastrointestinal (GI) tract to prevent damage to the microbiome, thereby limiting the overgrowth of pathogenic bacteria such as VRE (resistant enterococci). vancomycin) and reduce the incidence and severity of graft-versus-host disease (chronic GVHD) in recipients of allogeneic hematopoietic cell transplant (HCT); and (3) SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase (IAP) enzyme produced under cGMP conditions and intended to treat both local and GI diseases. For more information, visit Theriva Biologics’ website at www.therivabio.com.
For more information, contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608 one
Source: Theriva Biologics, Inc.
